Covetrus Inc. (CVET): Price and Financial Metrics
CVET Price/Volume Stats
Current price | $20.99 | 52-week high | $21.20 |
Prev. close | $20.93 | 52-week low | $13.39 |
Day low | $20.93 | Volume | 5,301,000 |
Day high | $21.00 | Avg. volume | 1,343,024 |
50-day MA | $20.86 | Dividend yield | N/A |
200-day MA | $18.83 | Market Cap | 2.94B |
CVET Stock Price Chart Interactive Chart >
Covetrus Inc. (CVET) Company Bio
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.
Latest CVET News From Around the Web
Below are the latest news stories about COVETRUS INC that investors may wish to consider to help them evaluate CVET as an investment opportunity.
Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. |
Covetrus Names Michelle Bonfilio as Chief People OfficerPORTLAND, Maine, September 26, 2022--Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. |
Moody's assigns B2 CFR to Covetrus, Inc.; Outlook StableThe ratings are being assigned in conjunction with a leveraged buyout of the company. Moody's also assigned B1 ratings to the company's proposed first-lien credit facilities, consisting of a $300 million bank revolving credit facility expiring 2027, and a $1,525 million term loan due 2029. |
Covetrus Names Margie B. Pritchard General CounselPORTLAND, Maine, August 26, 2022--Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. |
Covetrus Announces Retirement of Matthew FoulstonPORTLAND, Maine, August 11, 2022--Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced that Matthew Foulston, the Company’s Executive Vice President and Chief Financial Officer, has informed the company that he will be retiring from the company effective December 31, 2022. |
CVET Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 0.38% |
3-year | -14.64% |
5-year | N/A |
YTD | N/A |
2022 | 0.00% |
2021 | -30.51% |
2020 | 117.73% |
2019 | N/A |
2018 | N/A |
Loading social stream, please wait...